(Total Views: 147)
Posted On: 04/08/2022 11:01:54 AM
Post# of 44029
$USAQ USA Equities Corp. Reports Fourth Quarter and Full Year 2021 Financial Results
Fourth Quarter 2021 Revenue Up 265%
●
Revenue Surpassed $1.4 million for the year ended 2021 Compared to $124,000 for 2020
●
Gross Margin of 52% in Q4 Increased 1,200 Basis Points Versus Q4 2020
●
Strong balance sheet growth during 2021 with $2.2M in assets including the AllergiEnd® asset acquisition
●
Pending FINRA approval to change the Company’s Name to QHSLab, Inc.
West Palm Beach, FL, April 05, 2022 (GLOBE NEWSWIRE) -- USA Equities Corp (OTCQB: USAQ), a digital healthcare company focused on providing clinicians with artificial intelligence tools to leverage proactive, value-based healthcare solutions through the use of emerging digital and point of care technologies, announced its financial results for the fourth quarter and full-year 2021.
“The $1.6 million acquisition of the AllergiEnd® assets in June 2021 has created a robust strategic platform to build upon in 2022 and beyond. The revenue generated from AllergiEnd® product sales was $329,989 in the fourth quarter of 2021 compared to $124,532 for the same period in 2020 and $1,414,421 for the year 2021 compared to $124,532 for 2020. In addition, our physician practice clients generated approximately $5,000,000 in revenues utilizing our products during 2021. This is a huge benefit to our physician clients especially in this current climate of decreasing reimbursements for primary care physicians,” said USAQ CEO Troy Grogan.
https://finance.yahoo.com/news/usa-equities-c...00501.html
Fourth Quarter 2021 Revenue Up 265%
●
Revenue Surpassed $1.4 million for the year ended 2021 Compared to $124,000 for 2020
●
Gross Margin of 52% in Q4 Increased 1,200 Basis Points Versus Q4 2020
●
Strong balance sheet growth during 2021 with $2.2M in assets including the AllergiEnd® asset acquisition
●
Pending FINRA approval to change the Company’s Name to QHSLab, Inc.
West Palm Beach, FL, April 05, 2022 (GLOBE NEWSWIRE) -- USA Equities Corp (OTCQB: USAQ), a digital healthcare company focused on providing clinicians with artificial intelligence tools to leverage proactive, value-based healthcare solutions through the use of emerging digital and point of care technologies, announced its financial results for the fourth quarter and full-year 2021.
“The $1.6 million acquisition of the AllergiEnd® assets in June 2021 has created a robust strategic platform to build upon in 2022 and beyond. The revenue generated from AllergiEnd® product sales was $329,989 in the fourth quarter of 2021 compared to $124,532 for the same period in 2020 and $1,414,421 for the year 2021 compared to $124,532 for 2020. In addition, our physician practice clients generated approximately $5,000,000 in revenues utilizing our products during 2021. This is a huge benefit to our physician clients especially in this current climate of decreasing reimbursements for primary care physicians,” said USAQ CEO Troy Grogan.
https://finance.yahoo.com/news/usa-equities-c...00501.html
(0)
(0)
